

# Laquisa C Hill

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9242705/publications.pdf>

Version: 2024-02-01

21  
papers

287  
citations

1039880

9  
h-index

940416

16  
g-index

22  
all docs

22  
docs citations

22  
times ranked

463  
citing authors

#	ARTICLE	IF	CITATIONS
1	New and emerging therapies for acute and chronic graft-versus-host disease. Therapeutic Advances in Hematology, 2018, 9, 21-46.	1.1	90
2	Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies. Blood, 2019, 134, 199-199.	0.6	53
3	Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood, 2021, 137, 2585-2597.	0.6	38
4	The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clinical Advances in Hematology and Oncology, 2018, 16, 375-386.	0.3	15
5	Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood, 2022, 140, 16-24.	0.6	14
6	Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALL. Blood, 2022, 139, 2706-2711.	0.6	13
7	CD5 CAR T-Cells for Treatment of Patients with Relapsed/Refractory CD5 Expressing T-Cell Lymphoma Demonstrates Safety and Anti-Tumor Activity. Biology of Blood and Marrow Transplantation, 2020, 26, S237.	2.0	12
8	Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study. Leukemia and Lymphoma, 2021, 62, 3256-3263.	0.6	11
9	A phase I trial targeting advanced or metastatic pancreatic cancer using a combination of standard chemotherapy and adoptively transferred nonengineered, multi-antigen specific T cells in the first-line setting (TACTOPS).. Journal of Clinical Oncology, 2020, 38, 4622-4622.	0.8	9
10	Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma. Blood, 2021, 138, 654-654.	0.6	9
11	CAR-T cell therapy for non-Hodgkin lymphomas: A new treatment paradigm. Advances in Cell and Gene Therapy, 2019, 2, e54.	0.6	8
12	Beyond CD19 CAR-T cells in lymphoma. Current Opinion in Immunology, 2022, 74, 46-52.	2.4	3
13	37. Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T Cells Demonstrate Reactivity Against Emerging Variant Strains. Open Forum Infectious Diseases, 2021, 8, S27-S27.	0.4	3
14	Demographic and Clinical Donor Characteristics as Predictors of Total Nucleated Cell Concentrations in Harvested Marrow Products. Transplantation and Cellular Therapy, 2021, 27, 785.e1-785.e6.	0.6	2
15	Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19. Blood, 2020, 136, 5-5.	0.6	2
16	Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplantation, 2022, , .	1.3	2
17	COVID-specific T's may offset therapeutically endangered B's. Blood, 2022, 139, 12-13.	0.6	1
18	Health disparities experienced by Black Americans with multiple myeloma in the United States: A population-based study.. Journal of Clinical Oncology, 2021, 39, e18512-e18512.	0.8	0

#	ARTICLE	IF	CITATIONS
19	T Cell Immunity Toward Viral- and Tumor-Antigens Is Preserved in MDS Patients. Blood, 2019, 134, 4225-4225.	0.6	0
20	Outcomes of myeloablative, T cell deplete unrelated donor hematopoietic stem cell transplantation at a single center.. Journal of Clinical Oncology, 2020, 38, e19525-e19525.	0.8	0
21	Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL. Blood, 2021, 138, 471-471.	0.6	0